IGXT (MC $48 M) Great time to load up guys after they resubmit the NDA early this Week .
Market Cap : US$48 Million / Cash US$8.2 million /very low burn-rate of ~$700K a Quarter =Cash untill 2020+ EXCLUDING payments from new partnerships ,profitability expected quickly with approval for Rizaport and Tadalafil both approval expected in 2018, if everything goes well then this stock could run to $10 even then it wouldnt be expensive = ONE OF MOST ATTRACTIVE AND UNDERPRICED PHARMA STOCK YOU CAN GET AT THIS TIME .I LOVE IT
Intelgenx (IGXT)
Markt-Cap $48 Million Cash 8.1 Million Price: $0.73
FDA Decision for Rizaport(Migraine) in Q2/2018 (Peak Sales $60-80 Million)
NDA submission for Tadalafil (erectile dysfunction) this Quarter >> FDA approval in 2H 2018 (Peak Sales $150++ Million)
Start Phase 2a for Montulukast (Alzheimer disease) this Quarter >> Phase 2a Results in 1H/2018 (Potential BLOCKBUSTER Drug)
Opioid dependence drug partnered with Par Pharma >> FDA approval depends on patent ruling (Peak Sales $100++ Million) 30-Month Stay already expired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.